Protective efficacy of a Mycoplasma pneumoniae P1C DNA vaccine fused with the B subunit of Escherichia coli heat-labile enterotoxin

Canadian Journal of Microbiology

Volumn 58, Issue 6, 2012, Pages 802-810

  Zhu, Cuiming ^a,b   Wang, Shiping ^b   Hu, Shihai ^a   Yu, Minjun ^a   Zeng, Yanhua ^a   You, Xiaoxing ^a   Xiao, Jinhong ^a   Wu, Yimou ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b Central South University   (China)

Author keywords

DNA vaccine; Mycoplasma pneumoniae; P1 adhesin protein carboxy terminal region; The B subunit of escherichia coli heat labile enterotoxin

Indexed keywords

BACTERIUM ANTIBODY; DNA VACCINE; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN B SUBUNIT VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; MYCOPLASMA PNEUMONIAE ANTIBODY; MYCOPLASMA PNEUMONIAE P1 PROTEIN CARBOXY TERMINAL REGION DNA VACCINE; UNCLASSIFIED DRUG;

ANTIBODY; BACTERIUM; BIOTECHNOLOGY; DISEASE TREATMENT; HEATING; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; PNEUMONIA; PROTEIN; RODENT; TOXIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM DETECTION; COLONY FORMING UNIT; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG LAVAGE; MORTALITY; MOUSE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE LEVEL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; HOT TEMPERATURE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; RECOMBINANT PROTEINS; VACCINATION; VACCINES, DNA;

ESCHERICHIA COLI; MUS; MYCOPLASMA PNEUMONIAE;

EID: 84861692769     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/W2012-051     Document Type: Article

References (32)

1. Arrington, J., Braun, R.P., Dong, L., Fuller, D.H., Macklin, M.D., Umlauf, S.W., et al. 2002. Plasmid vector encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccine. J. Virol. 76(9): 4536-4546. doi:10.1128/JVI.76.9.4536-4546.2002. PMID:11932419.
2. Bébéar, C., Pereyre, S., and Peuchant, O. 2011. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 6(4): 423-431. doi:10.2217/fmb.11.18. PMID:21526943.
3. Block, S., Hedrick, J., Hammerschlag, M.R., Cassell, G.H., and Craft, J.C. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14(6): 471-477. doi:10.1097/00006454-199506000-00002. PMID:7667050.
4. Cassell, G.H., and Cole, B.C. 1981. Mycoplasmas as agents of human disease. N. Engl. J. Med. 304(2): 80-89. doi:10.1056/NEJM198101083040204. PMID:6777700.
5. Chaudhry, R., Nisar, N., Hora, B., Chirasani, S.R., and Malhotra, P. 2005. Expression and immunological characterization of the carboxy-terminal region of the P1 adhesin protein of Mycoplasma pneumoniae. J. Clin. Microbiol. 43(1): 321-325. doi:10.1128/ JCM.43.1.321-325.2005. PMID:15634989.
6. Cimolai, N., Taylor, G.P., Mah, D., and Morrison, B.J. 1992. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol. Immunol. 36(5): 465-478. PMID:1513263.
7. Dai, Z.B., Hu, S.H., Liu, Q.N., Chen, M., Wang, Y.F., Zhang, Y.K., et al. 2010. Improved immunologic responses of a vaccination regimen combining a DNA vaccine encoding LTB-PorB and recombinant LTB-PorB boosting. Chin. J. Immunol. 26(12): 1059-1063
8. Dallo, S.F., Su, C.J., Horton, J.R., and Baseman, J.B. 1988. Identification of P1 gene domain containing epitope(s) mediating Mycoplasma pneumoniae cytoadherence. J. Exp. Med. 167(2): 718-723. doi:10.1084/jem.167.2.718. PMID:2450165.
9. Dobbs, N.A., Odeh, A.N., Sun, X., and Simecka, J.W. 2009. The multifaceted role of T cell-mediated immunity in pathogenesis and resistance to mycoplasma respiratory disease. Curr. Trends Immunol. 10: 1-19. PMID:21743780.
10. Dumke, R., Lück, P.C., Noppen, C., Schaefer, C., von Baum, H., Marre, R., and Jacobs, E. 2006. Culture-independent molecular subtyping of Mycoplasma pneumoniae in clinical samples. J. Clin. Microbiol. 44(7): 2567-2570. doi:10.1128/JCM.00495-06. PMID: 16825381.
11. Fingerut, E., Gutter, B., Goldway, M., Eliahoo, D., and Pitcovski, J. 2006. B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet. Immunol. Immunopathol. 112(3-4):253-263. doi:10.1016/j.vetimm.2006.03.005. PMID: 16701905.
12. Hu, P.C., Huang, C.H., Collier, A.M., and Clyde, W.A., Jr. 1983. Demonstration of antibodies to Mycoplasma pneumoniae attachment protein in human sera and respiratory secretions. Infect. Immun. 41(1): 437-439. PMID:6862631.
13. Jacobs, E., Pilatschek, A., Gerstenecker, B., Oberle, K., and Bredt, W. 1990a. Immunodominant epitopes of the adhesin of Mycoplasma pneumoniae. J. Clin. Microbiol. 28(6): 1194-1197. PMID: 1696281.
14. Jacobs, E., Röck, R., and Dalehite, L. 1990b. A B cell-, T cell-linked epitope located on the adhesin of Mycoplasma pneumoniae. Infect. Immun. 58(8): 2464-2469. PMID:1695202.
15. Jones, H.P., and Simecka, J.W. 2003. T lymphocyte responses are critical determinants in the pathogenesis and resistance to mycoplasma respiratory disease. Front. Biosci. 8(1-3): d930-d945. doi:10.2741/1098.PMID:12700085.
16. Marshall, A.J., Miles, R.J., and Richards, L. 1995. The phagocytosis of mycoplasmas. J. Med. Microbiol. 43(4): 239-250. doi:10.1099/00222615-43-4-239 PMID:7562984.
17. Morozumi, M., Takahashi, T., and Ubukata, K. 2010. Macrolideresistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J. Infect. Chemother. 16(2): 78-86. doi:10.1007/s10156-009-0021-4. PMID:20094751.
18. Moyle, P.M., McGeary, R.P., Blanchfield, J.T., and Toth, I. 2004. Mucosal immunization: adjuvants and delivery system. Curr. Drug Deliv. 1(4): 385-396. doi:10.2174/1567201043334588. PMID: 16305400.
19. Rappuoli, R., Pizza, M., Douce, G., and Dougan, G. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heatlabile enterotoxins. Immunol. Today, 20(11): 493-500. doi:10.1016/S0167-5699(99)01523-6. PMID:10529776.
20. Rasmussen, J.N., Voldstedlund, M., Andersen, R.L., Ellermann-Eriksen, S., Jensen, T.G., Johansen, H.K., et al. 2010. Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 15(45): 19708. PMID:21087593.
21. Schurwanz, N., Jacobs, E., and Dumke, R. 2009. Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development. Infect. Immun. 77(11): 5007-5015. doi:10.1128/IAI.00268-09. PMID:19667041.
22. Tamura, S., Hatori, E., Tsuruhara, T., Aizawa, C., and Kurata, T. 1997. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine, 15(2): 225-229. doi:10.1016/S0264-410X(96)00135-1. PMID:9066042.
23. Verweij, W.R., de Haan, L., Holtrop, M., Agsteribbe, E., Brands, R., van Scharrenburg, G.J., and Wilschut, J. 1998. Mucosal immunoadjuvant activity of recombinant Escherichia coli heatlabile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine, 16(20): 2069-2076. doi:10.1016/S0264-410X(98)00076-0. PMID:9796066.
24. Waites, K.B., and Talkington, D.F. 2004. Mycoplasma pneumonia and its role as a human pathogen. Clin. Microbiol. Rev. 17(4): 697-728. doi:10.1128/CMR.17.4.697-728.2004. PMID: 15489344.
25. Wang, J., Hu, S.H., Dai, Z.B., Hu, Y.H., Zhang, Y.K., and Yu, M.J. 2010. Immunocompetence of a DNA vaccine of Neisseria gonorrhoeae surface protein A fused with B subunit of Escherichia coli heat labile enterotox. Chin. J. Immunol. 26(12): 968-972.
26. Wenzel, R.P., Craven, R.B., Davies, J.A., Hendley, J.O., Hamory, B.H., and Gwaltney, J.M., Jr. 1976. Field trial of an inactivated Mycoplasma pneumoniae vaccine. I. Vaccine efficacy. J. Infect. Dis. 134(6): 571-576. doi:10.1093/infdis/134.6.571. PMID:794422.
27. Wilson, M.H., and Collier, A.M. 1976. Ultrastructural study of Mycoplasma pneumoniae in organ culture. J. Bacteriol. 125(1): 332-339. PMID:54354.
28. Woolard, M.D., Hodge, L.M., Jones, H.P., Schoeb, T.R., and Simecka, J.W. 2004. The upper and lower respiratory tracts differ in their requirement of IFN-gamma and IL-4 in controlling respiratory mycoplasma infection and disease. J. Immunol. 172(11): 6875-6883. PMID:15153506.
29. Woolard, M.D., Hudig, D., Tabor, L., Ivey, J.A., and Simecka, J.W. 2005. NK cells in gamma-interferon-deficient mice suppress lung innate immunity against Mycoplasma spp. Infect. Immun. 73(10): 6742-6751. doi:10.1128/IAI.73.10.6742-6751.2005. PMID:16177352.
30. Xu, Y.C., Zhu, L.J., Xu, D., Tao, X.F., Li, S.X., Tang, L.F., and Chen, Z.M. 2011. Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumonia pneumonia in Hangzhou. World J. Pediatr. 7(3): 240-244. doi:10.1007/s12519-011-0318-0. PMID:21822990.
31. Yamamoto, M., McGhee, J.R., Hagiwara, Y., Otake, S., and Kiyono, H. 2001. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol. 53(3): 211-217. doi:10.1046/j.1365-3083.2001.00883.x. PMID:11251876.
32. Zhu, C, Wu, Y, Chen, S., Yu, M., Zeng, Y., You, X., et al. 2012. Protective immune responses in mice induced by intramuscular and intranasal immunization with an Mycoplasma pneumoniae P1C DNA vaccine. Can. J. Microbiol. 58(5): 644-652. doi:10. 1139/w2012-041. PMID:22540220.